Responses
Immunotherapy biomarkers
Original research
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group
Compose a Response to This Article
Other responses
No responses have been published for this article.
